Clinical Trials Logo

Asthma clinical trials

View clinical trials related to Asthma.

Filter by:

NCT ID: NCT02182700 Terminated - Asthma Clinical Trials

Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis

Start date: July 1998
Phase: Phase 3
Study type: Interventional

Study to evaluate the bronchodilator efficacy and safety of a fixed combination of salbutamol sulfate (120 mcg) + ipratropium bromide (20mcg) (Combivent® MDI) in aerosol plus spacer in adult patients with moderate-to-severe asthma crisis who arrived at the emergency room.

NCT ID: NCT02182661 Completed - Asthma Clinical Trials

A Long-term Study of Ba253BINEB in Patients With Bronchial Asthma

Start date: July 1998
Phase: Phase 3
Study type: Interventional

The objective of this study is to investigate the long-term safety of Ba253BINEB. Secondarily the long-term efficacy of Ba253BINEB is also investigated.

NCT ID: NCT02182505 Completed - Asthma Clinical Trials

Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma

Start date: September 1998
Phase: Phase 3
Study type: Interventional

Study to demonstrate that at least one of the two doses of Berodual® (50 µg fenoterol hydrobromide + 20 µg ipratropium bromide and 25 µg fenoterol hydrobromide + 10 µg ipratropium bromide, 1 puff t.i.d.) administered via Respimat® device gives a bronchodilator response which is not inferior to that obtained from one dose of Berodual® (50 µg fenoterol hydrobromide + 21 µg ipratropium bromide, 2 puffs t.i.d.) administered via the MDI (chlorofluorocarbon-metered dose inhaler) with Aerochamber® and that the safety profile is at least as good when paediatric asthma patients are treated for four weeks.

NCT ID: NCT02182479 Completed - Asthma Clinical Trials

Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients

Start date: April 1998
Phase: Phase 3
Study type: Interventional

Study to demonstrate that at least one of the two doses of Berodual® (50 µg fenoterol hydrobromide/20 µg ipratropium bromide and 25 µg fenoterol hydrobromide/10 µg ipratropium bromide, 1 puff q.i.d.) administered via Respimat® gives a bronchodilator response which is not inferior to that obtained from one dose of Berodual® (50 µg fenoterol hydrobromide/21 µg ipratropium bromide, 2 puffs q.i.d.) administered via MDI and that the safety profile is at least as good in asthma patients treated for 12 weeks.

NCT ID: NCT02181335 Completed - Asthma Clinical Trials

Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy

Start date: October 1998
Phase: Phase 3
Study type: Interventional

To establish that at least one of the two doses of Budesonide, as an ethanolic solution inhaled from the Respimat ® inhaler (100 and 200 mcg, 2 puffs bid) for a 12-week study period in symptomatic moderate to severe asthmatic patients, gives a therapeutic response, which is not inferior to that obtained from the dose of Budesonide inhaled from the Turbohaler ® (200 mcg, 2 puffs bid) and that the safety profile is at least as good

NCT ID: NCT02178059 Completed - Asthma Clinical Trials

Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Current Version of Turbohailer With Inhalation Via a New Version.

Start date: August 2014
Phase: Phase 1
Study type: Interventional

Relative bioavailability study to compare inhalation of Terbutaline Sulphate 1,5mg via current version of Turbohailer with inhalation via a new version

NCT ID: NCT02177370 Terminated - Asthma Clinical Trials

Effect on Fenoterol Metered Dose Inhaler on the Beta-receptor Population on Lymphocytes in Patients With Bronchial Asthma

Start date: February 1990
Phase: Phase 3
Study type: Interventional

The aim of the study was to compare the effect of fenoterol metered dose inhaler with disodium cromoglycate (DSCG) metered dose inhaler on the lymphocyte β2-receptor population as well as on the clinical findings in patients with bronchial asthma over a two-week period of treatment.

NCT ID: NCT02176694 Completed - Persistent Asthma Clinical Trials

Adolescent Controlled Text Messaging to Improve Asthma Medication Adherence in Primary Care

ACT Me
Start date: June 2014
Phase: N/A
Study type: Interventional

A randomized controlled trial of a texting intervention to increase adherence to preventative asthma medication in four Cincinnati Children's Hospital Medical Center primary care clinics.

NCT ID: NCT02175771 Completed - Persistent Asthma Clinical Trials

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Start date: July 2014
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the long-term safety of fluticasone propionate (Fp) inhalation powder in 2 strengths and fluticasone propionate/salmeterol inhalation (FS) powder in 2 strengths when administered with the Teva multidose dry powder inhaler (MDPI) device over 26 weeks in patients with persistent asthma.

NCT ID: NCT02173795 Completed - Asthma Clinical Trials

Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition

Start date: October 2002
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to investigate patients acceptability / preference of Berodual® Respimat® inhaler as compared to the conventional Berodual® Metered Aerosol (MA) inhaler. Ease of handling and assembling the Respimat® inhaler at home under real life conditions was also evaluated.